Rubius Therapeutics, Inc. (RUBY): Price and Financial Metrics
GET POWR RATINGS... FREE!
RUBY Stock Price Chart Interactive Chart >
RUBY Price/Volume Stats
| Current price | $0.26 | 52-week high | $6.76 |
| Prev. close | $0.25 | 52-week low | $0.14 |
| Day low | $0.24 | Volume | 206,830 |
| Day high | $0.27 | Avg. volume | 1,579,139 |
| 50-day MA | $0.21 | Dividend yield | N/A |
| 200-day MA | $0.68 | Market Cap | 23.54M |
Rubius Therapeutics, Inc. (RUBY) Company Bio
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest RUBY News From Around the Web
Below are the latest news stories about RUBIUS THERAPEUTICS INC that investors may wish to consider to help them evaluate RUBY as an investment opportunity.
Rubius Therapeutics Inc. (NASDAQ: RUBY) Stock Forecast: $3.00 Per Share In 2023 With Positive SignsIn the last trading session, 2.33 million shares of the Rubius Therapeutics Inc. (NASDAQ:RUBY) were traded, and its beta was 2.34. Most recently the company’s share price was $0.29, and it changed around $0.01 or 5.25% from the last close, which brings the market valuation of the company to $25.27M. RUBY currently trades at a … Rubius Therapeutics Inc. (NASDAQ: RUBY) Stock Forecast: $3.00 Per Share In 2023 With Positive Signs Read More » |
Pleasing stocks: Rubius Therapeutics, Inc. (NASDAQ:RUBY), Genius Brands International, Inc. (NASDAQ:GNUS)On 01-06-2023 (Friday) Shares of Rubius Therapeutics, Inc. (NASDAQ:RUBY) encountered a difference of -14.01% after which it shut the day’ session at $0.18. The volume added 1,927,795 shares which compares … The post Pleasing stocks: Rubius Therapeutics, Inc. (NASDAQ:RUBY), Genius Brands International, Inc. (NASDAQ:GNUS) appeared first on Stocks Equity . |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayThe final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! |
Rubius Therapeutics Inc.’s Stock Price Relatively Down Recently, But Trouble Is Still BrewingRubius Therapeutics Inc. (NASDAQ:RUBY) traded at $0.16 at close of the session on Tuesday, 01/03/23, made a downward move of -6.91% on its previous day’s price. Looking at the stock we see that its previous close was $0.17 and the beta (5Y monthly) reads 2.60 with the day’s price range being $0.16 – $0.1919. In … Rubius Therapeutics Inc.’s Stock Price Relatively Down Recently, But Trouble Is Still Brewing Read More » |
Stock Alert: Rubius Therapeutics, Inc. (NASDAQ:RUBY -6.91%), AlerisLife Inc. (NASDAQ:ALR 10.91%)Rubius Therapeutics, Inc. (NASDAQ:RUBY) with the stream of -6.91% also noticed, India AlerisLife Inc. (NASDAQ:ALR) encountered a rapid change of 10.91% in the last hour of Tuesday’s trading session. Rubius … The post Stock Alert: Rubius Therapeutics, Inc. (NASDAQ:RUBY -6.91%), AlerisLife Inc. (NASDAQ:ALR 10.91%) appeared first on Stocks Equity . |
RUBY Price Returns
| 1-mo | 48.57% |
| 3-mo | -25.86% |
| 6-mo | -64.38% |
| 1-year | -96.15% |
| 3-year | -96.67% |
| 5-year | N/A |
| YTD | 48.57% |
| 2022 | -98.19% |
| 2021 | 27.54% |
| 2020 | -20.11% |
| 2019 | -40.92% |
| 2018 | N/A |
Loading social stream, please wait...